GLP-1 drugs have 'little or no effect' on risk of obesity-related cancers, study suggests

Doctors say the class of medications that includes Ozempic and Zepbound still offers health benefits for people with diabetes ...
Devdiscourse

Race in Obesity Drugs Heats Up Amidst Legal Battles and Aid Crises

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...
Everyday Health on MSN

New Obesity Drug Helped People Lose Nearly One-Third Their Body Weight

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...
BioPharma Dive

Lilly’s three-pronged drug puts obesity field ‘on notice’

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

Zealand Pharma seeks to challenge GLP‑1 dominance with obesity drug aimed at long‑term use

Zealand Pharma plans to launch five obesity and related drugs by 2030 as the Danish company tries to break into the lucrative ...
Everyday Health

Zepbound vs. Wegovy: Which Obesity Treatment Might Be Right for You?

There’s no question that medications like semaglutide (Wegovy) and tirzepatide (Zepbound) have been making headlines lately. They’re two of the few injectable medications approved specifically for ...

Lilly Cuts Low-Dose Zepbound Price Up to 20% for Cash-Pay Buyers

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...

Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?

LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in ...